anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A minoxidil-containing composition for external use, said composition being stable, exhibiting a good feel of use and causing little irritation, that is a cream preparation characterized by comprising minoxidil, 1.5 parts by mass or more, per part by mass of minoxidil, of a higher fatty acid and/or a salt thereof, a thickener and a surfactant and being substantially free from lower alcohols, wherein minoxidil can be dissolved without employing a lower alcohol in such a large amount as usually required for dissolving minoxidil. Examples of the higher fatty acid and/or a salt thereof usable therein include isostearic acid and oleic acid. As an example of the thickener, a carboxyvinyl polymer can be cited. As an example of the surfactant, a nonionic surfactant can be cited. Further, the cream preparation may contain a polyhydric alcohol such as 1,3-butylene glycol, dipropylene glycol, glycerol or propylene glycol. The pH value of the cream preparation is preferably 5-8.
FIELD: pharmacy. SUBSTANCE: powdery composition has hydrated ceftibuten taken at effective amount with about 7-14 weight % water, substance exhibiting opacity, at least one sweetening substance and thickening agent and, additionally, nonionogenic surface-active substance and antifoaming agent taken at effective amount. Thickening agent is taken from the group involving silicon dioxide, magnesium aluminosilicate, mixture of microcrystalline cellulose and carboxymethylcellulose at weight ratio = (6:1)-(10:1), xanthane resin and their mixtures being thickening agent is taken at amount effective for suspension condensing. Also, invention relates to method of preparing the powdery composition containing hydrated cephalosporin useful for suspending in water and used as an oral preparation. Method involves mixing hydrated cephalosporin or its pharmaceutically tolerated salt as a solid powder with dry pharmaceutically tolerated carriers involving agents indicated above at room temperature under moistened condition. Prepared dry mixture is fed in the closed capacity that is opaque for visible light spectrum. Hydrated cephalosporin or its salt is mixed additionally with surface-active substance and antifoaming agent and preserving agent and the obtained dry mixture is fed in the sealed capacity under atmosphere at maximal oxygen content about 5 vol.%. EFFECT: improved method of preparing.
Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
OBJECTIVES: I. Determine the complete and overall response rate to paclitaxel in patients with previously untreated extensive stage small cell lung cancer. II. Determine the overall and progression free survival of these patients in response to this treatment regimen. III. Determine the toxicity of this treatment regimen in this patient population.

OUTLINE: This is a multicenter study. Patients receive paclitaxel IV over 3 hours weekly for 6 consecutive weeks. Treatment continues every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, then every 3 months for 2 years, and then annually for 2 years.
Methods: The randomized double blinded clinical trial will recruit 414 healthy kindergarten children aged 3-5 years old with caries and with parental consent. The sample size is sufficient for the appropriate statistical analyses. The children will receive 0.004 mL 38% SDF (typical amount applied per manufacturer's instructions) to treat each caries lesion. The children will be classified into high and low caries rates and equably allocated into nine groups of SDF application time: 3, 5, 15, 30, 45, 60, 120 and 180 seconds. The children will be followed up for 6-months in their kindergartens. Clinical examinations after 6-months will be conducted to assess whether the caries is arrested. Information on confounding factors, such as oral hygiene habits and the use of other fluoride agents, will be collected through a parental questionnaire at the baseline and 6-months follow-up. The examiner, the children and the children's parents will be blind to the treatment allocation. The analysis will determine the significance of differences between the means of arrested caries at the various follow-ups; and Cochran-Armitage test will be used to evaluate the exposure (SDF-application time) to response relationship.

Significance: This study will help determine the optimal application time in SDF treatment. The study provides an evidence-based protocol for the use of silver diamine fluoride to arrest tooth decay in primary teeth of young children.
Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
PURPOSE:To obtain an analgesic and antiinflammatory drug useful for mammal containing human effectively prevent disease of tunica mucosa ventriculi, containing ascorbic acid, analogues of said acid and aspirin analogue compound, etc. CONSTITUTION:At least, a species of ascorbic acid and analogue of said acid and at least a species of aspirin analogue compound are contained in the objective drug. An inorganic salt of ascorbic acid, fatty acid ester of ascorbic acid or inorganic acid ester of ascorbic acid is used as the ascorbic acid analogue and acetyl salicylic acid, aluminum acetyl salicylate, choline salicylate or sodium salicylate, etc., is used as the aspirin analogue compound. Besides, >=0.1 pt.wt. ascorbic acid or analogue of said acid is used to 1 pt.wt. the aspirin analogue compound.
This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
An estimated 2.3% of children suffer from encopresis. Enhanced Toilet Training (ETT) is one of the most effective ways of treating this disorder. When delivered by skilled and knowledgeable clinicians, ETT is twice as effective as intensive medical management alone. Although ETT is effective in treating encopretic children, there are six major barriers to its implementation: 1) availability of a knowledgeable and skilled clinician; 2) parental acceptance of referral to a mental health professional; 3) expense of service; 4) burden of time and distance to access such specialty services; 5) child resistance to disclosure of embarrassing material; and 6) willingness of the child and parent to follow treatment recommendations. This project will circumvent these barriers by developing an interactive Internet-based ETT program. The study will then assess the feasibility of the program by determining the acceptance, function, and effectiveness of the intervention.

This project will have four phases. Phase 1 will identify optimal Internet and treatment elements as well as issues in need of experimental investigation. Phase 2 will investigate how to enhance Internet interventions. Phase 3 will evaluate the relative benefit of adding the Internet treatment to clinical services provided by clinicians in the fields of medicine and mental health. Phase 4 will investigate the relative long-term benefits of adding such an Internet-based intervention to professional care to determine its impact on symptom improvement, relapse prevention, quality of life, and its cost-effectiveness. Phase 4 will also assess to what extent the program is disseminated worldwide when made available on the Internet.
FIELD: biotechnology, biochemistry, enzymes. SUBSTANCE: method involves the use of insulin production waste as the parent raw for pancreatic ribonuclease preparing. Method involves ultrafiltration on the hollow fibers followed by treatment with activated carbon for RNAse preparation purification. Method ensures to increase the yield of the end product by 10-fold. EFFECT: improved method of preparing, increased yield. 2 cl, 1 tbl
The Treatment Group will receive the same periodontal treatment in addition to having subgingival chlorhexidine irrigation. All subjects will also complete a set of questionnaires (PANAS \& PMT) using an online form. A subset of 50 subjects from each group will be randomly selected to have oral images captured using an intra-oral scanner at Baseline and a subset of follow-up visits. Additionally, subjects in the Treatment Group will also receive brief behavioral advice from dental professionals focusing mainly on motivation and acknowledgement.
Transcranial direct current stimulation (tDCS), a noninvasive neuromodulation technique, applied to the left dorsolateral prefrontal cortex (DLPFC) can reduce depressive symptoms and improve cognitive control in major depressive disorder (MDD). Such findings suggest modulation of top down prefrontal-limbic circuits, which are functionally distinct from ventro-limbic networks and include reciprocally connected DLPFC and dorsomedial anterior cingulate cortex (dACC). However, substantial variation in tDCS response is observed in MDD. This may be due to imprecise stimulation protocols and suboptimal engagement of the neural circuits mediating antidepressant response. Methods that optimize electrode placement and account for individual variation in anatomy and that map current flow directly in the brain may inform the mechanisms and potential clinical utility of tDCS. A new tDCS technique, high definition (HD) tDCS, offers more focal stimulation than conventional tDCS (C-tDCS). The degree to which C-tDCS or HD-tDCS engage dorsal prefrontal-limbic neural circuits is unknown, yet is vital for understanding, confirming and subsequently improving possible therapeutic effects. Innovative MRI techniques that are able to map tDCS currents in vivo and that track changes in regional cerebral blood flow occurring with tDCS over time can provide direct evidence of neural effects. Based on a) theoretical modeling of tDCS current flow, b) studies showing hypo-metabolism, decreased CBF or activity in dorsal prefrontal-limbic networks, c) modulation of these regions with treatment, and, c) our prior results showing significant relationships in between change in dACC rCBF and clinical response to electroconvulsive therapy (ECT), an established brain stimulation treatment, we will test for the tDCS engagement and modulation of the DLPFC and dACC using tDCS current mapping performed in vivo and perfusion MRI. MRI-guided neuronavigation will be used to optimize and standardize electrode placement for DLPFC stimulation.

In this trial we will test for the target engagement of the DLPFC and dACC by comparing C-tDCS, HD-tDCS and sham tDCS applied to the left DLPFC in patients with moderate to severe MDD before and after they complete 12 daily 20-minute sessions of C-tDCS, HD-tDCS or Sham tDCS (n=20 randomized to each group). In-vivo electric current mapping performed at different current intensities (0-2 mA) for 20-30 minutes, and change in regional cerebral blood flow (rCBF) measured before and after a 12-day tDCS trial will determine acute and longer-term modulation of DLPFC and dACC circuitry for each tDCS modality respectively.
Intraosseous vancomycin plus cefazolin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep of the leg and draping has occurred prior to skin incision and after the tourniquet has been inflated. The injection will take place into the tibial tubercle, which is a known safe IO injection site. The IO injection will include 500mg of vancomycin and a 1g dose of cefazolin, previously used in prior IO studies of cefazolin.
Participants in the Treatment as Usual group (TAU) will not receive the Brief PE therapy, but the standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months from Baseline.
The invention relates to a preparation method of a novel oral ulcer antibacterial film. The oral ulcer antibacterial film comprises, by weight: 1-20% of polyvinyl alcohol, 1-10% of polyacrylic acid, 0.5-5% of glycerol, 2-10% of water-soluble chitosan, 0.1-5% of bioactive glass, and the balance distilled water. The bioactive glass is evenly dispersed in the glycerol, and the bioactive glass and the glycerol are in a ratio of 1:0.5-1:2. Specifically, the bioactive glass comprises, by weight: 24.5% of CaO, 24.5% of NaO, 45% of SiO2, and 6% of P2O5. During preparation of the oral ulcer antibacterial film provided by the invention, under an aseptic condition, polyacrylic acid, polyvinyl alcohol, a mixed solution of bioactive glass and glycerol, and chitosan are added into distilled water in order, and during adding, the temperature, stirring time, complete dissolution and the pH value of the solution are controlled, thus finally obtaining a film-like material. The oral ulcer antibacterial film provided by the invention has good biocompatibility and degradability, and also has very good bacteriostatic and wound repair functions, thus being applicable to prevention and treatment of oral ulcer.
PCT No. PCT/JP96/03701 Sec. 371 Date Jun. 19, 1998 Sec. 102(e) Date Jun. 19, 1998 PCT Filed Dec. 19, 1996 PCT Pub. No. WO97/22595 PCT Pub. Date Jun. 26, 1997Novel arylethenesulfonamide derivative having a high affinity for drugs, especially endoserine receptors, and represented by general formula (I); pharmaceutically acceptable salts thereof; and drugs comprising the same as the active ingredient, especially endoserine receptor antagonist, wherein Ar: optionally substituted aryl group or optionally substituted five- to six-membered heteroaryl group; X: oxygen atom, sulfur atom or a group represented by a formula -NH-; Y: oxygen atom or sulfur atom; R1: hydrogen atom, optionally halogen-substituted lower alkyl group, cycloalkyl group, optionally substituted aryl group or optionally substituted five- to six-membered heteroaryl group. R2: lower alkyl group, lower alkenyl group or lower alkynyl group where each of which may be substituted with one to three substituent(s) selected from a group consisting of hydroxyl group, lower alkoxy group, cycloalkyl group, halogen atom, carboxyl group and lower alkoxycarbonyl group; R3: phenyl group which may be substituted with one to four substituent(s) selected from a group consisting of optionally halogen-substituted lower alkyl group, lower alkoxy group, halogen atom, lower alkylthio group, lower alkylsulfinyl group, lower alkanesulfonyl group, carboxyl group, lower alkoxycarbonyl group and carbamoyl group; and R4 and R5: they may be same or different and each is hydrogen atom or lower alkyl.
Following the baseline assessment, participants will be randomly assigned to one of the study groups. This treatment group will include a Notched Noise Therapy, a 1-10 kHz noise "notched" within a 1-octave range centered around the psychoacoustic tinnitus pitch match measured. Randomized participants will wear their hearing aids with this loaded software for 8 weeks. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort.
Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
The invention relates to the technical field of medicines, and in particular relates to a composition and application thereof in preparing medicines for treating inflammation-related diseases. The composition comprises polydatin and emodin. At least one of naringin, glycyrrhizic acid and liquiritin is also added into the composition. The invention also discloses application of the composition in preparing a medicament for treating inflammation-related diseases. The invention discovers the synergistic action of the polydatin and the emodin, and the polydatin and the emodin have more obvious anti-inflammatory efficacy under the synergistic action than the single action. The composition can effectively inhibit the weight reduction of mice infected by the influenza A H1N1 virus, inhibit the expression of inflammatory factors and obviously improve the pulmonary symptoms of the infected mice, thereby being used for treating pneumonia caused by the influenza A H1N1 virus.
Fexmid® (cyclobenzaprine hydrochloride) is a white, crystalline tricyclic amine salt. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride, and has the following structural formula:

Fexmid is available for oral administration as 7.5 mg tablets. Fexmid contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate, hydroxypropyl cellulose, hypromellose, polyethylene glycol, magnesium stearate, microcrystalline cellulose, and titanium dioxide.
In a first aspect the present invention consists of T cell epitopes in the Hepatitis C virus genome. More specifically there is provided 429 linear peptide epitopes from the Hepatitis C Virus genome. In a second aspect the invention also consists of variants of these sequences. In a third aspect this invention consists of a method to predict these sequences from genome data and to validate the predictions experimentally. Ina fourth aspect the present invention provides compositions including these epitopes for use in a vaccine and to induce a T cell response in a subject, or as a diagnostic tool. Figure 2 shows a plot of the measured versus the predicted binding affinity score for four different prediction methods (1) Rammensee matrix method, (b) Hidden Markov model trained on sequences in the Rammensee dataset, (c) Neural network trained with sparse sequence encoding, and (d) The Comb-II neural network method.
Retinal degenerations are a group of inherited diseases that result in progressive death of the vision cells, or photoreceptors. Currently there is no treatment or cure for any of these diseases and they ultimately cause blindness in affected patients. We propose to investigate the structure and function of the human retina in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO). We will correlate the images of retinal structure produced by the AOSLO with Optical Coherence Tomography (OCT) images of the retina. In addition, we will study the vision of individual photoreceptors using the AOSLO to perform a novel technique, microperimetry, in patients with retinal degenerations. We will compare the results of microperimetry with standard measures of vision used in Ophthalmology clinics, including visual acuity, automated perimetry, fundus photography and multifocal electroretinography (mfERG).

The results of this work will provide insight into the mechanism of vision loss among patients with diverse retinal disorders. Specifically, we will study cone structure and function in patients with retinal degenerations with different etiologies: retinitis pigmentosa, a disease usually caused by rod-specific mutations; cone-rod dystrophy, which primarily affects cones rather than rods; and Best's disease, a disease caused by a defect in the retinal pigment epithelium (RPE). In addition, we will study the effect that lipofuscin, a byproduct of photoreceptor metabolism that accumulates in the RPE in diseases such as Stargardt's disease, Best's disease and age-related macular degeneration (AMD), has on cone structure and function, with the goal of understanding how these diseases cause blindness. Better understanding of the mechanisms of vision loss in patients with retinal degeneration should ultimately lead to treatments for these blinding conditions.
Based on additive or synergistic effect of natural killer (NK) cell and chemotherapy (modulating the expression of NK stimulatory ligand on tumor cell), the investigators performed phase II trial of docetaxel and ANKL combination s the second line treatment in advanced non-small cell lung cancer (NSCLN) and reported the results in May 2013. (Anticancer Research 33;2115, Poster Presentation in ASCO).In that study, the investigators observed the feasibility and safety of ANKL combined with docetaxel in patients with advanced NSCLC, but the clinical benefit was not evaluated properly because the study was interrupted unintentionally and most of the enrolled patients were far advanced with large tumor burden, that is, poor immunological environment for ANKL to work.

The object of this study is to identify the combined effect of ANKL and doublet chemotherapy in advanced NSCLC. The approved doublet chemotherapy based on platinum is widely used with the response rate (RR) 25-35% after 4-6 courses as the first line treatment. The investigators design the combination of ANKL and chemotherapy as the 3rd and 4th courses in the patients who show stable response after x2 courses. Higher RR with the combination treatment is the primary outcome as compared with the chemotherapy alone - historical control; about 12% PR and 50% stable response after x2 initial courses and 25% PR after x2 more courses among the patients who get stable response after x2 initial courses. Peripheral blood 32 ml will be drawn from the patients who decide to be enrolled and about 2 weeks later ANKL (2x10\*9) are scheduled to be administered rapidly iv 12-36hr after each chemotherapeutic agents while peak effect of NK cell ligand modulation by chemotherapeutic agent is maintained. After 4th course, response evaluation is done by RECIST and 40% or more PR (increased by 15% or more from historical control 25%) is the expected target and Simon's two stage design will be applied through the study (power 80%, a= 0.95, N1= 33, N= 68)
Patients will receive pharmacotherapy based on methylphenidate (18 mg per tablet) with a 3-week titration phase to a maximum dose of 108 mg per day, with a weekly follow-up during 3 months. Socio-demographic and behavioral data will be collected through phone interviews every month. During medical visits, self-administered and clinical questionnaires will collect clinical and behavioral data. Urine drug toxicologies and blood sampling will be performed to gather biological, pharmacokinetic and pharmacodynamic data.

This study should identify an effective response-dose of methylphenidate for people with a cocaine use disorder. The methylphenidate should be effective to reduce cocaine use in cocaine-dependent individuals with a good tolerability. The results of pharmacokinetic and pharmacodynamic analyses will give us the effective dose of methylphenidate and some information on toxicity to adapt the surveillance in a future clinical trial.
The patients (n=150) will be recruited for the study from patients who applied to the psychiatric clinic in Sheba, new patients, old patients and patients on the waiting list. In addition, patients from the various psychiatric departments and the psychiatric and general ER at the Sheba Medical Center - Tel Hashomer. In addition, a recruitment ad will be published on social networks.